Inhibiting the glycerophosphodiesterase EDI3 in ER-HER2+ breast cancer cells resistant to HER2-targeted therapy reduces viability and tumour growth.

Magdalena KellerKatharina RohlfAnnika GlotzbachGregor LeonhardtSimon LükeKatharina DerksenÖzlem DemirciDefne GöçenerMohammad AlWahshJörg LambertCecilia LindskogMarcus SchmidtWalburgis BrennerMatthias BaumannEldar ZentMia-Lisa ZischinskyBirte HellwigKatrin MadjarJörg RahnenführerNina OverbeckJörg ReindersCristina CadenasJan G HengstlerKarolina EdlundRosemarie Marchan

Published in: Journal of experimental & clinical cancer research : CR (2023)

Our results indicate that EDI3 may be a potential novel therapeutic target in patients with HER2-targeted therapy-resistant ER-HER2 + breast cancer that should be further explored.

Keyphrases

breast cancer cells
endoplasmic reticulum
signaling pathway
human health
climate change